NASDAQ:MYNZ Mainz Biomed (MYNZ) Stock Price, News & Analysis → Trump conviction scandal exposed (From Porter & Company) (Ad) Free MYNZ Stock Alerts $0.87 +0.15 (+20.86%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$0.72▼$1.0150-Day Range$0.56▼$1.1252-Week Range$0.55▼$6.00Volume798,630 shsAverage Volume184,379 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice Target$6.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrends Get Mainz Biomed alerts: Email Address Mainz Biomed MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside590.3% Upside$6.00 Price TargetShort InterestHealthy1.75% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.45Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.97 out of 5 stars 3.3 Analyst's Opinion Consensus RatingMainz Biomed has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageMainz Biomed has only been the subject of 2 research reports in the past 90 days.Read more about Mainz Biomed's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.75% of the float of Mainz Biomed has been sold short.Short Interest Ratio / Days to CoverMainz Biomed has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Mainz Biomed has recently decreased by 25.54%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMainz Biomed does not currently pay a dividend.Dividend GrowthMainz Biomed does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MYNZ. Previous Next 2.5 News and Social Media Coverage News SentimentMainz Biomed has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Mainz Biomed this week, compared to 2 articles on an average week.Search Interest8 people have searched for MYNZ on MarketBeat in the last 30 days. This is an increase of 700% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Mainz Biomed to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mainz Biomed insiders have not sold or bought any company stock.Percentage Held by Insiders18.20% of the stock of Mainz Biomed is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Mainz Biomed's insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Mainz Biomed is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mainz Biomed is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMainz Biomed has a P/B Ratio of 3.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Mainz Biomed's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyThis military-backed stock “owns” AI marketThe AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. About Mainz Biomed Stock (NASDAQ:MYNZ)Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.Read More MYNZ Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MYNZ Stock News HeadlinesMay 31 at 5:01 PM | globenewswire.comMainz Biomed Reports Results of 2024 Annual General MeetingMay 30 at 5:56 AM | americanbankingnews.comMainz Biomed (NASDAQ:MYNZ) Short Interest Down 25.5% in MayMay 28, 2024 | finanznachrichten.deEQS-News: Mainz BioMed N.V.: Mainz Biomed präsentiert neue gepoolte Daten seiner bisher größten Darmkrebs-Screening-Studie auf der ASCO 2024May 28, 2024 | globenewswire.comMainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual MeetingMay 28, 2024 | americanbankingnews.comMainz Biomed (NASDAQ:MYNZ) Shares Up 1.6%May 20, 2024 | globenewswire.comMainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA TrialMay 7, 2024 | finanznachrichten.deEQS-News: Mainz BioMed N.V.: Mainz Biomed präsentiert Ergebnisse der Darmkrebsfrüherkennungsstudie eAArly DETECT auf der Digestive Disease Week 2024May 7, 2024 | globenewswire.comMainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.April 30, 2024 | uk.news.yahoo.comStrictly Come Dancing's Shirley Ballas shares important cancer update to fansApril 25, 2024 | globenewswire.comMainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer DiagnosticApril 17, 2024 | msn.comMainz Biomed N.V. (MYNZ) Price Target Decreased by 9.09% to 5.10April 10, 2024 | finance.yahoo.comThe Pharmaceutical Industry Finds Itself At A Historical CrossroadsApril 9, 2024 | investorplace.comMYNZ Stock Earnings: Mainz Biomed Beats EPS, Misses Revenue for Q4 2023April 9, 2024 | markets.businessinsider.comEQS-News: Mainz Biomed Reports Full Year 2023 Financial ResultsApril 9, 2024 | globenewswire.comMainz Biomed Reports Full Year 2023 Financial ResultsApril 5, 2024 | seekingalpha.comMYNZ Mainz Biomed N.V.April 2, 2024 | benzinga.comPharma's Post-Pandemic Story To Unlock A Cancer-Free EraMarch 19, 2024 | markets.businessinsider.comEQS-News: Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer TreatmentMarch 19, 2024 | globenewswire.comMainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer TreatmentMarch 18, 2024 | markets.businessinsider.comEQS-News: Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic OptionsMarch 18, 2024 | globenewswire.comMainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic OptionsMarch 12, 2024 | finanznachrichten.deMainz BioMed NV: Mainz Biomed Presents ColoAlert at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening InnovationsMarch 12, 2024 | globenewswire.comMainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening InnovationsMarch 5, 2024 | globenewswire.comMainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer DiagnosticFebruary 27, 2024 | markets.businessinsider.comEQS-News: Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical CommunitySee More Headlines Receive MYNZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mainz Biomed and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/09/2024Today6/01/2024Next Earnings (Estimated)6/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MYNZ CUSIPN/A CIK1874252 Webmainzbiomed.com Phone49-6131-554-2860FaxN/AEmployees65Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$9.00 Low Stock Price Target$3.00 Potential Upside/Downside+590.3%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-26,300,000.00 Net Margins-2,934.82% Pretax Margin-2,938.10% Return on Equity-488.05% Return on Assets-145.77% Debt Debt-to-Equity Ratio0.36 Current Ratio0.97 Quick Ratio0.91 Sales & Book Value Annual Sales$900,000.00 Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.27 per share Price / Book3.22Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta0.28 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Guido Baechler (Age 59)CEO & Executive Director Mr. William J. Caragol (Age 57)Chief Financial Officer Dr. Christopher Von Torne P.M.P. (Age 52)Ph.D., Chief Operating Officer Dr. Frank Krieg-Schneider (Age 62)Chief Technology Officer Dr. Moritz Eidens Ph.D. (Age 40)Chief Science Officer & Executive Director Stefan ErlachHead of Human ResourcesMr. Philipp Freese (Age 41)Chief Business Officer Mr. Darin S. Leigh (Age 56)Chief Commercial Officer More ExecutivesKey CompetitorsLAVA TherapeuticsNASDAQ:LVTXNLS PharmaceuticsNASDAQ:NLSPOncoSec MedicalNASDAQ:ONCSQPharvarisNASDAQ:PHVSProcaps GroupNASDAQ:PROCView All Competitors MYNZ Stock Analysis - Frequently Asked Questions Should I buy or sell Mainz Biomed stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Mainz Biomed in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MYNZ shares. View MYNZ analyst ratings or view top-rated stocks. What is Mainz Biomed's stock price target for 2024? 2 brokers have issued 12-month target prices for Mainz Biomed's shares. Their MYNZ share price targets range from $3.00 to $9.00. On average, they expect the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 590.3% from the stock's current price. View analysts price targets for MYNZ or view top-rated stocks among Wall Street analysts. How have MYNZ shares performed in 2024? Mainz Biomed's stock was trading at $1.16 at the beginning of 2024. Since then, MYNZ shares have decreased by 25.1% and is now trading at $0.8692. View the best growth stocks for 2024 here. Are investors shorting Mainz Biomed? Mainz Biomed saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 300,900 shares, a decrease of 25.5% from the April 30th total of 404,100 shares. Based on an average trading volume of 119,400 shares, the short-interest ratio is presently 2.5 days. Approximately 1.8% of the company's shares are short sold. View Mainz Biomed's Short Interest. When is Mainz Biomed's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, June 4th 2024. View our MYNZ earnings forecast. How were Mainz Biomed's earnings last quarter? Mainz Biomed (NASDAQ:MYNZ) released its earnings results on Tuesday, April, 9th. The company reported ($0.24) EPS for the quarter. The firm had revenue of $0.22 million for the quarter. Mainz Biomed had a negative trailing twelve-month return on equity of 488.05% and a negative net margin of 2,934.82%. When did Mainz Biomed IPO? Mainz Biomed (MYNZ) raised $10 million in an initial public offering on Friday, November 5th 2021. The company issued 2,000,000 shares at a price of $4.00-$6.00 per share. Boustead Securities acted as the underwriter for the IPO. How do I buy shares of Mainz Biomed? Shares of MYNZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MYNZ) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProShocking: One AI startup's revenue could surge 4,735%Manward PressMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mainz Biomed Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
